Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma

NCT01101594 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT01101594
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01101594 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma
Lead sponsor
Gilead Sciences
Phase
Phase 1/2
Overall status
Terminated
Start date
July 31, 2010
Completion date
July 31, 2013
Enrollment
17 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma